A free diabetes, endocrinology and medical news article resource for endocrinologists and physicians. Endocrinology conference coverage and drug information.

2024年6月14日 · Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Glucagon-like peptide-1 (GLP-1) is a hormone released …

2 天之前 · Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of …

2025年1月24日 · Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2 mg in adults with obesity. The randomized, double-blinded, parallel-group, …

2025年1月24日 · Use of a hybrid closed-loop insulin delivery system reduces risk for hypoglycemic coma but increases risk for diabetic ketoacidosis, according to results of a study …

4 天之前 · Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse …

2024年4月2日 · Addison’s disease — also referred to as primary adrenal insufficiency — occurs when the adrenal glands do not produce enough cortisol and/or aldosterone, hormones …

4 天之前 · The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney …

Type 2 diabetes mellitus is a metabolic disorder characterized by dysregulation of blood glucose caused by relative insulin deficiency and insulin resistance. 1 It is a progressive condition that …

2024年2月28日 · Empagliflozin vs cardioprotective glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with lower risks for major adverse cardiovascular events (MACEs) …